Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.
⁃ Expected survival time of ≥3 months. Refractory moderate - to - severe active systemic sclerosis that has failed standard treatment or lacks effective therapeutic options.
⁃ Meets the requirements for liver and kidney function, as well as cardiopulmonary function.
⁃ Free from severe psychiatric disorders. Able to understand the trial and has signed the informed consent form.
Locations
Other Locations
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Qiubai Li, MD
qiubaili@hust.edu.cn
+8613995671635
Time Frame
Start Date: 2025-05-30
Estimated Completion Date: 2040-01
Participants
Target number of participants: 24
Treatments
Experimental: UTAA91 injection
Related Therapeutic Areas
Sponsors
Leads: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology